FDA lifts clinical hold on Avidity’s lead antibody conjugate therapy trial
Two years after the FDA placed partial clinical hold, Avidity can resume research of del-desiran as a treatment for myotonic dystrophy type 1.
Two years after the FDA placed partial clinical hold, Avidity can resume research of del-desiran as a treatment for myotonic dystrophy type 1.
What's Your Reaction?
